Abstracts tagged "obesity"

Abstract Number: 0581 • ACR Convergence 2025
Effects of Apremilast on Body Mass Index, Weight, and HbA1c as Cardiometabolic Outcomes in Patients With Early Oligoarticular Psoriatic Arthritis in the FOREMOST Study
Philip J. Mease¹, Álvaro González Cantero², Jennifer Soung³, April Armstrong⁴, Joseph F Merola⁵, Fabian Proft⁶, Laure Gossec⁷, Dafna D. Gladman⁸, Laura Coates⁹, Lichen Teng¹⁰, Jimena Vázquez¹¹, Cynthia Deignan¹² and Arthur Kavanaugh¹³, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Dermatology, Ramón y Cajal University Hospital, Madrid, Spain, ³Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, ⁴University of California Los Angeles, Los Angeles, ⁵Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁶Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷Sorbonne Université, Pitié Salpêtrière Hospital, Paris, France, ⁸Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ¹⁰Amgen Inc., Thousand Oaks, ¹¹Amgen Inc., Thousand Oaks, CA, ¹²Amgen, Inc., Agoura Hills, CA, ¹³University of California, San Diego, School of Medicine, San Diego, CA
Background/Purpose: The prevalence of cardiometabolic diseases, including obesity and diabetes, is higher in patients with psoriatic arthritis (PsA) than those without PsA.1,2 Metabolic syndrome is…
Abstract Number: 1011 • ACR Convergence 2025
Model-based Evaluation of the Potential Public Health Impact of Expanding Medicare Coverage for Weight Loss Medications for Beneficiaries with Knee Osteoarthritis and Obesity in the US.
Ethan Eickmann¹, Daniel Betensky¹, Karen Smith¹, Candace Feldman¹, Jason Kim², Ankur Pandya³, Jeffrey Katz⁴ and Elena Losina⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Arthritis Foundation, Atlanta, GA, ³Harvard School of Public Health, Boston, ⁴Brigham and Women's Hospital, Brookline, MA, ⁵BWH, Boston, MA
Background/Purpose: US federal law currently does not allow Medicare Part D coverage for weight loss medications without additional indications, such as diabetes. Several glucagon-like peptide-1…
Abstract Number: 1027 • ACR Convergence 2025
GLP-1 Receptor Agonists to Facilitate Weight Loss and Improve Disease Activity, Pain and Function in Patients With Rheumatic and Musculoskeletal Disease: Real-World Evidence From the Rheumatology Informatics System for Effectiveness (RISE) Registry
Nick McCormick¹, Jingyi Zhang², Emily Holladay², Fenglong Xie³ and Jeffrey Curtis⁴, ¹Auburn University, Auburn, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL, ⁴Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) such as semaglutide (SEM; GLP-1) and tirzepatide (TIR; GIP/GLP-1), were initially approved for type 2 diabetes management but…
Abstract Number: 1130 • ACR Convergence 2025
Novel Anti-Obesity Medications and Serum Urate Change Among Patients with Gout and Baseline Hyperuricemia
Kiara Tan¹, Jiaqi Wang¹, Saiajay Chigurupati², Gregory Challener³, Natalie McCormick¹, Sharan Rai⁴, Florence Porterfield⁵, Chika Anekwe¹, Dong Wook Kim⁶, Fatima Stanford⁷, Caroline Apovian⁸, Hyon K. Choi⁹ and Chio Yokose¹⁰, ¹Massachusetts General Hospital, Boston, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ⁴Massachusetts General Hospital/Harvard Medical School, Boston, MA, ⁵Division of Endocrinology, Massachusetts General Hospital, Boston, ⁶Division of Endocrinology, Diabetes and Hypertension, Brigham and Women’s Hospital, Boston, ⁷Neuroendocrine Unit, Pediatric Endocrinology, Massachusetts General Hospital, Boston, ⁸Brigham and Women's Hospital, Boston, ⁹MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ¹⁰Massachusetts General Hospital, Waltham, MA
Background/Purpose: Obesity affects >50% of individuals with gout and is the most important modifiable risk factor for gout. Thus, novel anti-obesity medications (AOM, e.g., semaglutide…
Abstract Number: 1383 • ACR Convergence 2025
Obesity in Primary Sjogren’s Disease
Gabriela Hernandez-Molina¹, Donaji Gómez-Velasco², Ariel Garcia-Torralba², Carlos Aguilar-Salinas² and Ivette Cruz-Bautista², ¹Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Federal District, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Obesity is an excessive fat accumulation that presents a risk to health. Little is known about the relationship between obesity and Sjögren’s disease (SjD).…
Abstract Number: 1484 • ACR Convergence 2024
A Retrospective Evaluation of Glucagon-like Peptide-1 Receptor Agonists in SLE Patients
Philip Carlucci¹, Brooke Cohen², Amit Saxena³, H Michael Belmont³, Mala Masson⁴, Heather Gold⁵, Jill Buyon² and Peter Izmirly⁶, ¹New York University School of Medicine, New York, NY, ²NYU Grossman School of Medicine, New York, NY, ³NYU School of Medicine, New York, NY, ⁴NYU Langone Health, New York, NY, ⁵NYU Langone Health, NYC, ⁶New York University Grossman School of Medicine, New York, NY
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP1-RA) are an emerging class of medications that significantly improve cardiometabolic outcomes. Whether these drugs may be useful in mitigating…
Abstract Number: 1891 • ACR Convergence 2024
Association of Physical Activity Levels on Chronic Opioid Use in Radiographic Axial Spondylitis Patients
Rutvin Kyada¹, Jean Liew², Maureen Dubreuil³, Matthew Brown⁴, Mariko Ishimori⁵, John Reveille⁶, Michael Ward⁷, Michael Weisman⁸ and Lianne S Gensler⁹, ¹Boston University, Boston, MA, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³Section of Rheumatology, Boston University School of Medicine, Boston, MA, ⁴King's College London, London, United Kingdom, ⁵Cedars-Sinai Health System, Los Angeles, CA, ⁶UTHealth Houston Division of Rheumatology, Houston, ⁷NIH, Bethesda, MD, ⁸Stanford University, Los Angeles, CA, ⁹Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Pain remains a common symptom of axial spondyloarthritis (axSpA) despite availability of effective therapies. Physical activity may benefit pain and is guideline recommended but…
Abstract Number: 2114 • ACR Convergence 2024
CT and DXA Bone Fragility Evaluation After Bariatric Surgery
Marine FAUNY¹, Marion Halin², Edem Allado², Laurent Brunaud², Claire Nomine Criqui², Eliane Albuisson², Isabelle Chary-Valckenaere³, Damien Loeuille⁴ and Didier Quilliot², ¹CH TOUL, Toul, Lorraine, France, ²Nancy University Hospital, Vandoeuvre, Lorraine, France, ³Nancy University Hospital, Vandœuvre-lès-Nancy, Lorraine, France, ⁴Phd, Nancy Vandoeuvre, Lorraine, France
Background/Purpose: Bariatric surgery could impact bone metabolism and induce significant changes, leading to increased bone resorption and an increased risk of fractures.The primary objective was…
Abstract Number: 2237 • ACR Convergence 2024
The Association Between Bariatric Surgery and Incident Rheumatoid Arthritis
Helana Jeries¹, Revital Perlov Gavze², Rula Daood³, Fadi Hassan³, Liat Lev shalem⁴, Ahmad Assalia⁵ and Mohammad E Naffaa³, ¹Rheumatology Unit, Galilee Medical Center, Naharyia, Israel, Naharyia, HaZafon, Israel, ²Maccabi Healthcare Services, Tel Aviv, Israel, ³Rheumatology Unit, Galilee Medical Center, Naharyia, Israel, Naharyia, Israel, ⁴Maccabi Healthcare Services, Tel Aviv, HaMerkaz, Israel, ⁵Rambam Healthcare Campus, Haifa, HaZafon, Israel
Background/Purpose: Obesity is considered a controversial risk factor for developing rheumatoid arthritis (RA), and the association between weight change and RA incidence is inconclusive. The…
Abstract Number: 2259 • ACR Convergence 2024
Effects of Anti-Obesity Medications in RA Patients
Elizabeth Dente¹, David Kellner², Vincent Tran², Travis Welsh², Victor Tran³, Angshuman Saha¹, Jenny Brook¹, David Elashoff⁴ and Veena Ranganath², ¹UCLA, Los Angeles, ²UCLA, Los Angeles, CA, ³UCLA, Costa Mesa, CA, ⁴UCLA Department of Medicine Statistics Core, Los Angeles
Background/Purpose: It is standard practice to advocate for weight loss in patients with rheumatoid arthritis (RA) and obesity. Obesity and rheumatoid arthritis are both independently…
Abstract Number: 2350 • ACR Convergence 2024
Do Smoking and Obesity Impact Secukinumab Treatment Outcomes? Real-world Data from 1,202 European Patients with Psoriatic Arthritis
Zohra Faizy Ahmadzay¹, Stylianos Georgiadis², Mikkel Ostergaard³, Bente Glintborg⁴, Signe Møller-Bisgaard⁵, Marion Pons⁶, Jette Heberg⁷, Sara Nysom Christiansen⁸, Simon Horskjær Rasmussen⁶, Anne Gitte Loft⁹, Isabel Castrejon¹⁰, Lucia Otero-Varela¹¹, Jakub Závada¹², Karel Pavelka¹², Jarno Rutanen¹³, Laura Kuusalo¹⁴, Michael Nissen¹⁵, Ziga Rotar¹⁶, Katja Perdan-Pikmajer¹⁶, Miguel Bernardes¹⁷, Bjorn Gudbjornsson¹⁸, Gerdur Gröndal¹⁸, Irene E. van der Horst-Bruinsma¹⁹, Karin Laas²⁰, Brigitte Michelsen²¹, Catalin Codreanu²², Daniela DiGuiseppe²³, Burkhard Moeller²⁴, Gökçe Kenar²⁵, Merete Hetland²⁶ and Lykke Oernbjerg², ¹Rigshospitalet Glostrup and Copenhagen University, Glostrup, Denmark, ²Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ³Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ⁴DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ⁵Rigshospitalet, Glostrup and Slagelse Hospital, Glostrup, Denmark, ⁶Rigshospitalet Glostrup, Glostrup, Denmark, ⁷Rigshospitalet Glostrup, København V, Denmark, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark., Glostrup, Denmark, ⁹Aarhus University Hospital and Aarhus University, Horsens, Denmark, ¹⁰Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain, ¹¹Spanish Society of Rheumatology, Madrid, Spain, ¹²Institute of Rheumatology and Charles University, Praha, Czech Republic, ¹³Tampere University Hospital, Tampere, Finland, ¹⁴University of Turku and Turku University Hospital, Turku, Finland, ¹⁵Geneva University Hospital, Geneva, Switzerland, ¹⁶University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹⁷São João Hospital Center and FMUP, Lisboa, Portugal, ¹⁸Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹⁹Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ²⁰East-Tallinn Central Hospital, Tallinn, Estonia, ²¹Rigshospitalet, Glostrup and Diakonhjemmet Hospital and Sørlandet Hospital, Kristiansand, Norway, ²²University of Medicine and Pharmacy, Bucharest, Romania, ²³Karolinska Institutet, Stockholm, ²⁴Inselspital - University Hospital Bern, Bern, Switzerland, ²⁵Dokuz Eylul University School of Medicine, Izmir, Turkey, ²⁶Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark
Background/Purpose: Smoking and obesity are common in patients with psoriatic arthritis (PsA) and can lead to higher disease activity and poorer response to treatment with…
Abstract Number: 2386 • ACR Convergence 2024
Landscape of Immune Cells and Autoimmunity in Systemic Lupus Erythematosus Patients with Obesity
Alexandra Reese¹, Chandana Keshavamurthy², Sneha Centala¹, Samantha Ahrens¹, Shivani Shah², Douglas Reeves², William Davis³, Robert Quinet⁴, Jerald Zakem¹, Qingli Wu¹, Kimmy Tran¹, Teresa Leeth⁵, Daniyal Nadeem⁶, Sarwat Umer⁷, Samina Hayat⁵ and Xin Zhang¹, ¹Ochsner Health, New Orleans, LA, ²Ochsner Clinic Foundation, New Orleans, ³Ochsner Health System, New Orleans, LA, ⁴Ochsner Health, River Ridge, LA, ⁵Louisiana State University Shreveport, Shreveport, LA, ⁶LSU Shreveport, Shreveport, ⁷LSU HEALTH SHREVEPORT, SHREVEPORT, LA
Background/Purpose: Systemic lupus erythematosus (SLE) is an inflammatory autoimmune disease characterized by autoantibodies and disruption of multiple organs due to immunomodulatory dysfunction. Obesity is a…
Abstract Number: 0294 • ACR Convergence 2024
Obesity and Risk of Autoimmune Diseases: Insights from the National Inpatient Sample
Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY
Background/Purpose: Obesity has been implicated as a risk factor in developing various cardiovascular, respiratory, and other health complications. However, the link between obesity and autoimmune…
Abstract Number: 0388 • ACR Convergence 2024
The Association Between Body Composition and Disease and Treatment Outcomes in Patients with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
Samantha Morin¹, KAREN BEATTIE², Roxana Bolaria³, Tania Cellucci⁴, Gaelle Chedeville⁵, Amieleena Chhabra⁶, Paul Dancey⁷, Tommy Gerschman⁸, Liane Heale⁹, Julie Herrington², Adam Huber¹⁰, Mehul Jariwala¹¹, Jean-Philippe Proulx-Gauthier¹², Dax Rumsey¹³, Heinrike Schmeling¹⁴, Jaime Guzman¹⁵ and Michelle Batthish⁴, and CAPRI Registry Investigators, ¹McMaster University, Hamilton, Canada, ²McMaster University, Hamilton, ON, Canada, ³Victoria Arthritis Center, Victoria, BC, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada, ⁵The Montreal Children's Hospital, Montreal, QC, Canada, ⁶University of British Columbia, Penticton, BC, Canada, ⁷Memorial University, St. John's, Canada, ⁸University of British Columbia - Vancouver, North Vancouver, BC, Canada, ⁹McMaster University, Oakville, ON, Canada, ¹⁰IWK Health Centre, Halifax, NS, Canada, ¹¹Jim Pattison Children's Hospital, Saskatoon, Canada, ¹²CHU de Quebec - Universite Laval, Quebec, QC, Canada, ¹³University of Alberta, Edmonton, AB, Canada, ¹⁴University of Calgary, Calgary, AB, Canada, ¹⁵University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: Recent evidence has linked abnormal body weight, underweight or obesity, with poor disease outcomes in adults with inflammatory arthritis. Yet, little is known about…
Abstract Number: 0438 • ACR Convergence 2024
Overweight and Obesity Are Key Modifiable Risk Factors for Adverse Outcomes in SLE Pregnancies
Jessica Boivin¹, Karim Sacre², Sasha Bernatsky³, Ann E. Clarke⁴, Megan Barber⁴, Paul Fortin⁵, John Hanly⁶, Alexandra Legge⁷, Sang-Cheol Bae⁸ and Evelyne Vinet⁹, ¹McGill University, Montreal, QC, Canada, ²Université de Paris, Paris, France, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁶Dalhousie University, Halifax, NS, Canada, Halifax, NS, Canada, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁹McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: High maternal body mass index (BMI) is a well-established modifiable risk factor for adverse pregnancy outcomes (APO) in the general obstetric population. Best practices…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].